Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 12/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.90 |
| ▸ | TUBB4A | P04350 | 8/20 | 0.59 |
| ▸ | TUBB | P07437 | 8/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 8/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 8/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 8/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 8/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 8/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 8/20 | 0.59 |
| ▸ | TUBB8 | Q3ZCM7 | 8/20 | 0.59 |
| ▸ | TUBA3E | Q6PEY2 | 8/20 | 0.59 |
| ▸ | TUBA1A | Q71U36 | 8/20 | 0.59 |
| ▸ | TUBA1C | Q9BQE3 | 8/20 | 0.59 |
| ▸ | TUBB6 | Q9BUF5 | 8/20 | 0.59 |
| ▸ | TUBB2B | Q9BVA1 | 8/20 | 0.59 |
| ▸ | TUBB1 | Q9H4B7 | 8/20 | 0.59 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837006 | 0.95 | PDGFRB (1.00) | EGFRPDGFRBKDRPDGFRATUBB4A | |
| SCHEMBL22432673 | 0.82 | PDGFRB (0.78) | EGFRPDGFRBKDRPDGFRATUBB4A | |
| SCHEMBL19242608 | 0.82 | EGFR (0.69) | EGFRPDGFRBKDRPDGFRATUBB4A | |
| SCHEMBL16622677 | 0.79 | TUBB4A (0.89) | EGFRPDGFRBKDRPDGFRATUBB4A | |
| SCHEMBL22432671 | 0.77 | EGFR (0.71) | EGFRPDGFRBKDRPDGFRATUBB4A | |
| SCHEMBL16622703 | 0.74 | TUBB4A (1.00) | EGFRPDGFRBKDRPDGFRATUBB4A | |
| SCHEMBL18551428 | 0.73 | TUBB4A (0.67) | EGFRPDGFRBKDRPDGFRATUBB4A | |
| SCHEMBL17837026 | 0.72 | PDGFRB (1.00) | EGFRPDGFRBKDRPDGFRA | |
| SCHEMBL16612695 | 0.72 | TUBB4A (0.76) | EGFRPDGFRBKDRPDGFRATUBB4A | |
| SCHEMBL16612578 | 0.72 | TUBB4A (0.76) | EGFRPDGFRBKDRPDGFRATUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200290976-A1 | RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-09-17 | — | — | US | disclosed |
| US-10189853-B2 | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189853-B2 | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170369500-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369500-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-12-28 | — | — | US | disclosed |
| US-9777012-B2 | Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777012-B2 | Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777012-B2 | Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2016100495-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100495-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176891-A1 | Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-06-23 | — | — | US | disclosed |
| US-20160176891-A1 | Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-06-23 | — | — | US | disclosed |
| US-20160176891-A1 | Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176891-A1 | Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents | ERBB2, MAP2, TUBB6 | EGFR 8/4885PDGFRB 232/4885KDR 167/4885 |
| US-20170369500-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS | ERBB2, DCK, DHFR | EGFR 38/4885PDGFRB 394/4885KDR 402/4885 |
| US-10189853-B2 | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents | ERBB2, DCK, DHFR | EGFR 38/4885PDGFRB 394/4885KDR 402/4885 |
| US-20200290976-A1 | RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF | TUBB3, MAP2, MAPT | EGFR 1574/4885PDGFRB 944/4885KDR 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.